4 results
The primary objective(s) of this study is:- To determine the relative bioavailability of etoricoxib 120 mg tablets manufactured at Frosst Iberica, Spain and Elkton, VA, USA.
The purpose of the study is to investigate how quickly and to what extent rivastigmine is absorbed and eliminated from the body when administered RTS for 7 days (this is called pharmacokinetics) as well as the safety of RTS.
Primary Objective: To investigate the effect of treatment with nebulized rhDNase targeted to the peripheral airways compared to rhDNase targeted to the central airways on FEF75 in children with CF who are on maintenance treatment with rhDNase.…
To compare the rate and extent of rivastigmine absorption from two different formulations of 7-day rivastigmine transdermal systems (7-day RTS) with 24-hour Exelon® patch applied daily for 7 days in healthy adult male and female subjects.To assess…